A two-phase HCM regimen uses mavacamten to reduce hypercontractility while tapering beta blockers, improving exercise capacity and symptoms.
Combining HDAC inhibition, stem-cell-based vaccination, and a TLR3 adjuvant boosts MHC-I antigen presentation to target resistant cancer stem cells.
Prodrug STAT3 inhibitors block pathogenic IL-6/STAT3 signaling to restore Teff/Treg balance, reduce IL-17, and suppress autoimmunity.
Fumaric acid esters raise fetal hemoglobin through an alternative pathway to ease sickle cell symptoms with fewer hydroxyurea-related risks.